Shire submits SPD465 for adult ADHD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire's attention deficit/hyperactivity disorder agent SPD465 has an estimated May 21, 2007 user fee date following the firm's July 21 submission. The amphetamine compound is designed to provide sustained release of medication for 16 hours. SPD465 has the same active ingredient as the firm's Adderall XR (mixed amphetamine salts), which provides treatment for 12 hours...